Fourteen current and former MD Anderson researchers were represented in 11 of the 50 most-cited Journal of Clinical Oncology (JCO) articles from 2012, according to the journal, which is produced by the American Society of Clinical Oncology.
The results, reported in the March 16 online edition of JCO, cited four articles with lead authors from MD Anderson:
Hagop Kantarjian, M.D., chair of Leukemia. “Multicenter Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia”; 22 citations.
Naoto Ueno, M.D., Ph.D., professor of Breast Medical Oncology. “Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors;” 23 citations.
Anas Younes, M.D., now at Memorial Sloan-Kettering Cancer Center. “Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma”; 52 citations.
Razelle Kurzrock, M.D., now at the University of California, San Diego. “PI1K/AKT/mTOR Inhibitors in Patients with Breast and Gynecologic Malignancies Harboring PIK2CA Mutations”; 33 citations.
In addition, 10 current or former MD Anderson researchers were contributing authors on the list of 50 most-cited articles, including Robert Gagel, M.D.; William Wierda, M.D., Ph.D.; Michelle Fanale, M.D.; Sherry Pierce, Research Nurse Manager in Leukemia; Farhad Ravandi-Kashani, M.D.; Stefan Faderl, M.D., who is now at the John Theurer Cancer Center in New Jersey; Jaffer Ajani, M.D.; Santiago Gonzalez-Moreno, M.D., Ph.D.; Hagop Kantarjian, M.D.; and Guillermo Garcia-Manero, M.D.